Over the last four weeks there were 59,648 cases of COVID in the region, and over the last week there has been an decrease of 10,940 cases and it appears that we may be over the peak of the recent COVID surge – however we continue to urge vigilance as number of COVID cases are still high.
Please note that the actual number of cases is likely to be much more. For further information please go to the latest NSW COVID statistics.
Infection control and wearing masks (staff and patients) is critically important. Practices are asked to ensure that their most vulnerable populations are fully vaccinated and where possible to ensure children with respiratory illnesses get access to care. If you would like an infectious control consultation or any other support, email email@example.com
HealthPathways – upcoming changes to the COVID suite of pathways
HealthPathways is regularly updated with the latest information on COVID. Please note that the following pathways have been updated on HealthPathways for both South Eastern Sydney and Sydney)
COVID-19 Shared Care: retired
COVID-19 Self-care Patient Triage and Support: retired
COVID-19 Active Case Management – title will change to COVID-19 Management.
Please be assured that all the information from the pathways that were retired is retained on the COVID-19 Management (SES & Sydney) pathway.
Update: use of antivirals in residential aged care
With influenza continuing to circulate in the community alongside COVID-19 it is important to protect our most vulnerable, including residents of residential aged care facilities (RACF).
The Commonwealth Department of Health has distributed oseltamivir and molnupiravir to RACF for use in residents. To assist with this, NSW Health has enacted legislation to permit RACF’s to hold and store both these medications. Note that:
Molnupiravir and nirmatrelvir/ritonavir are now also available on the Pharmaceutical Benefits Scheme (PBS) for residents of RACF through community pharmacies.
Oseltamivir(Tamiflu®) can be used in residents with confirmed influenza or for prophylactic use in exposed residents during influenza outbreaks in RACFs. Use of this medicine may shorten the duration and severity of the illness.
Molnupiravir(Lagevrio®) and Nirmatrelvir/ritonavir (Paxlovid™) can be used in people with confirmed COVID-19 in the community (including in RACF) with mild to moderate symptoms who are immunosuppressed or who are aged over 50 and at risk of severe disease OR people who are aged 70 and over whether they have symptoms or not. The drug should be commenced as early as possible but no later than day 5 after symptom onset.
The administration of antiviral treatments soon after symptom onset for people with COVID-19 or influenza can reduce disease severity. Additionally, the administration of influenza antivirals to residents of RACF after exposure improves clinical outcomes and assists in controlling the outbreak.
CESPHN and NSW Health are working with general practitioners and providers of RACF to make sure residents are aware of these medications and can receive them as soon as they need them.
Vaccination for children aged 6 months to under 5 years
Following the Therapeutic Goods Administration’s (TGA) approval of the Moderna vaccine for children aged 6 months to 5 years, the Australian Technical Advisory Group on Immunisation (ATAGI) recommends COVID-19 vaccination for children aged 6 months to under 5 years with severe immunocompromise, disability, and those who have complex and/or multiple health conditions which increase the risk of severe COVID-19.
The recommendation is for 2 primary doses, except for those children with severe immunocompromise who will require 3 primary doses. The recommended interval between each dose is 8 weeks. At this stage, ATAGI does not recommend vaccination for children aged 6 months to under 5 years who are not in the risk categories for severe COVID-19. These children have a very low likelihood of severe illness from COVID-19.
Advice: Paxlovid post labelled expiry date
The Therapeutic Goods Administration (TGA) is advising that nirmatrelvir + ritonavir (PAXLOVID) tablet blister packs for the batch numbers below, can be used up to the revised (‘new’) expiry date, provided that approved storage conditions of storage below 25 °C have been maintained.
Fourth dose eligibility and COVID boosters
ATAGI has updated its recommendations for an additional booster dose (fourth dose) for selected population groups who are at greatest risk of severe illness from COVID-19. This quick reference guide can be used by vaccine providers to assist in identifying patients eligible for a 4th dose of a COVID-19 vaccine.
Please encourage COVID booster doses as many people in our region are not receiving maximal protection from COVID-19 see the ATAGI Latest Update . Adults aged 65 years or older who have not yet received a winter dose of COVID-19 vaccine should get this as soon as possible. Booster doses in older adults, will help reduce the number of COVID-19 related hospitalisations over the coming months.
Please consider the use of antiviral treatment in people diagnosed with COVID-19, including in people aged 50 years and above and reinforce messages on mask wearing.
The interval between the first booster and the winter booster (4th dose) has been reduced to 3 months (from 4 months) to provide earlier protection from the additional vaccine during winter.
COVID at Home visiting service
We encourage GPs to refer to the COVID@Home Service which provides an ‘in-home’ assessment service delivered by a Registered Nurse with the support of a GP.
This service is for COVID positive patients whose regular GP is not able to undertake home visits but where such a visit is required for medical and other support reasons while the patient is isolating. Referrals will only be accepted from GPs. Find out more about the service and how to refer. If you have any enquiries, contact firstname.lastname@example.org.
Free infection control advice on Zoom
We are offering specialised one-on-one Zoom consultations with an experienced primary care infection control educator to assist with infection control procedures.
GPs should consider facilitating either telehealth or in person consultation for patients with respiratory symptoms. When in person consultation is indicated, the patient should be given a surgical mask and hand sanitiser and practice staff should wear eye protection and a mask.
To book a session, email your interest to email@example.com with the subject line: “Yes I would like infection control advice”.
CESPHN Vax at Home service
The CESPHN Vax at Home Service is for those people who are housebound and not able to leave their house to receive a COVID-19 vaccination or booster. The service will accept referrals for people 16 years and over. Referrals will be accepted from GPs and from Local Health Districts. Patient self-referrals will not be accepted.
All Vax at Home Service referrals must be sent through this Vax at Home Service Online Form. Please also indicate if an influenza vaccine is also required. Please note, a referral will need to be attached to the online form. For further information on the program, please contact us.
Ordering process for PPE
Access to PPE is now via Living with COVID PPE Bundles ordered nationally through PHNs using an online order form and delivered directly by a national distributor (rather than via PHNs). Access to PPE from the National Medical Stockpile is dependent on eligibility, and PPE volumes will be monitored by the Commonwealth Department of Health.
General Practice, ACCHS and GPRCs ordering information
Living with COVID PPE Bundles are available for:
GP, ACCHS and GPRCs willing to manage COVID positive patients face-to-face, until 30 September 2022.
ACCHSs and rural and remote GPs willing to treat COVID positive patients virtually and respiratory patients face-to-face, where workforce capacity is limited AND the GP is serving the community for most of all health needs, until 30 September 2022.
GPs and GPRCs willing to support COVID positive people virtually, and respiratory patients face to face, until 30 September 2022.
Orders can only be placed once per month and be submitted to the PHN via the online form.
Please read the guidance document before placing your first order:
Individual patients – we have access to a small supply of oximeters. GPs with patients they believe require a pulse oximeter urgently are asked to complete this CESPHN Pulse Oximeter online form with the patients details and we will arrange delivery of an oximeter.
General practices – practices actively seeing moderate risk COVID positive patients can also be sent up to 10 pulse oximeters per practice via the new PPE online ordering form. If your practice has already received 10 pulse oximeters via the previous process, you will need to access future stock through your local suppliers.
COVID-19 response update
About: primary care update on the COVID-19 response and the vaccine rollout – key updates and Q&A
Thursday 11 August 2022 at 11:30am (AEST) – Click link to join
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
Continuing Professional Development (CPD) annual requirements Below is a snapshot of the continuing professional development (CPD) requirements for doctors, these include annual requirements of: completion of a Professional Development Plan 50 hours CPD each year, split across a range of activities: 25 hours – reviewing performance and measuring outcomes (with five hours minimum…
CESPHN’s Annual Report 2022-23 is now live Central and Eastern Sydney PHN has released its Annual Report 2022-23. The Annual Report is a summary of the key achievements and highlights for the PHN over the financial year. It is split into Improving Care Integration, Improving Practice and Commissioning Services to…